Founded in 2008, Castle Biosciences is a leading molecular diagnostics company focused on improving health through innovative tests that guide patient care. Our corporate headquarters is in Friendswood, Texas with laboratory facilities located in Phoenix, Arizona and Pittsburgh, Pennsylvania.
Realizing a large unmet clinical need in disease management, we continuously strive to evolve and improve, challenging the status quo with scientific expertise, valuable insights and robust data development.
Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing clinicians, with a primary focus in dermatologic and gastroenterological disease.
Our two core revenue-driving tests are: (1) the DecisionDx®-Melanoma test for invasive cutaneous melanoma, a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors; and (2) the TissueCypher® Barrett’s Esophagus test, designed to predict progression to esophageal adenocarcinoma (EAC), the most common form of esophageal cancer, in patients with Barrett’s esophagus, the only known precursor condition to EAC.
DecisionDx®-SCC is our GEP test designed to predict the risk of metastasis and local recurrence in patients with high-risk squamous cell carcinoma, as well as identify which patients are most likely to benefit from adjuvant radiation therapy. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test designed to predict the risk of metastasis for patients with uveal melanoma, a rare eye cancer. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. AdvanceAD-Tx™ is our newest GEP test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis. The test addresses a major unmet need by helping physicians match patients to the right treatment class to help avoid trial-and-error prescribing.
Additionally, we have active research and development programs for tests in these and other diseases with high unmet clinical need, including ongoing initiatives to increase both our current dermatologic and gastrointestinal offerings. We also look to put the strength of our balance sheet to work through a disciplined and strategic approach to capital deployment, focusing on creating stockholder value.